Erratum

Erratum on “Eltrombopag as first-line treatment in severe aplastic anemia: a cost-effectiveness analysis from the Brazilian public healthcare system perspective”

M.A. Salvino a,b, C. Bonfim c, R.T. Calado d, H. Kim e, J.F. Bertinato e, P. Scheinberg f

a Hospital Universitário Professor Edgar Santos (HUPES), Universidade Federal da Bahia (UFBA), Salvador, BA, Brazil
b Hospital São Rafael, Instituto D’Or de Ensino e Pesquisa (IDOR), Salvador, BA, Brazil
c Blood and Marrow Transplantation Unit, Department of Hematology, Hospital de Clínicas da Universidade Federal do Paraná (UFPR), Curitiba, PR, Brazil
d Department of Medical Imaging, Haematology, and Clinical Oncology, Faculdade de Medicina de Ribeirão Preto (FMRP), Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil
e Novartis Biociências S.A., São Paulo, SP, Brazil
f Division of Hematology, A Beneficência Portuguesa de São Paulo (BP), São Paulo, SP, Brazil

ARTICLE INFO

Article history:
Available online 12 April 2022


Where it reads:
“This resulted in an incremental cost of R$ 116,268 per patient treated with IST alone.”

It should read:
“However, the combination saved resources related to HSCT, relapse and end of life. This resulted in an incremental cost of R$ 96,002 per patient treated with IST alone.”

Where it reads:
resulting in an ICER of R$ 83,412 per life-year gained.

it should read:
“resulting in an ICER of R$ 68,872 per life-year gained.”